title: Targeting other abnormal signaling pathways in sarcoma: EGFR in synovial sarcomas, PPAR-gamma in liposarcomas.
authors.affiliation: Unité d'Oncologie Médicale, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
authors.forename: Isabelle
authors.initials: I
authors.lastname: Ray-Coquard
authors.forename: Laurent
authors.initials: L
authors.lastname: Alberti
authors.forename: Dominique
authors.initials: D
authors.lastname: Ranchère
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D066246:ErbB Receptors / Q000378:metabolism*; D006801:Humans; D008080:Liposarcoma / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D015514:Oncogene Proteins, Fusion / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D013584:Sarcoma, Synovial / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D015398:Signal Transduction / Q000187:drug effects*; D014157:Transcription Factors / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D015514:Oncogene Proteins, Fusion; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D066246:ErbB Receptors